XRP's price stuck despite key upgrades & SEC clarity. Geopolitics & Clarity Act are wildcards.
LMB's 11.9% revenue growth & 46.5% EPS growth at 17.8x P/E. SEZL's 68.1% revenue growth & 323% EPS growth at 13.6x P/E. ENVA's 23.8% revenue growth & 38% EPS growth at 8.7x P/E.
3M+ eye drops recalled over safety! Investors eye pharma risks & potential impact on healthcare sector valuations.
DASH surges 931% EPS on 22% order growth, trading at 17.8x EV/EBITDA. PCAR & CSCO face revenue dips & lower margins.
MEDP's 26.9% FCF margin & 31.7% EPS growth shine. CCL's 9.5% FCF & low returns raise flags.
BETR jumps 23% on expanded credit facility, betting on e-commerce warehouse demand. Is it a buy?
SAIC's 1.2% sales decline & 10.1x P/E raise flags. NE's 40.7% gross margin & 42.9x P/E caution. UPST's 51.6% origination growth & 2x P/S shines.
Sponsored
Must Read